From the 1960s to the early 1980s, due to insufficient research on the natural clinical course and the natural regression of liver pathology in chronic HBV carriers, and the lack of scientific epidemiological studies on the relative risk of developing cirrhosis and hepatocellular carcinoma, most scholars and doctors in the liver disease community believed that chronic HBV carriers did not need treatment. It was not until the mid-1980s that more and more research has been conducted in the above-mentioned areas on chronic HBV (hepatitis B virus) carriers at home and abroad, which has led to a new and more scientific understanding of the natural course, regression, hepatic pathological changes and relative risk of developing cirrhosis and hepatocellular carcinoma in chronic HBV carriers. The remaining 90% have varying degrees of liver pathology, of which 10% have significant chronic liver lesions. In long-term observation, it was found that 15-40% of chronic HBV carriers developed cirrhosis and hepatocellular carcinoma (especially the small triplets after mother-to-child transmission). The factors that lead to the development of cirrhosis and hepatocellular carcinoma in chronic HBV carriers are complex, among which the activation of HBV-X gene and the long-term persistence and development of chronic inflammation and proliferative changes of hepatocytes in the liver are considered to be the key factors. This shows that in chronic HBV infection, strategies to control and prevent hepatocellular carcinoma are key to the treatment of minor triplets. Minor triplets must be treated aggressively if HBV-DNA exceeds the standard (positive changes) and there are changes in liver function such as increased ALT. The treatment principle of chronic hepatitis minor tri-positive: emphasize three points of medicine treatment, seven points of conditioning, the spirit should be happy, life should be regular, pay attention to the reasonable arrangement of diet, liver function jaundice or ALT significant rise in bed rest, the choice of antiviral drugs, adjust the immune function drugs, blood circulation, anti-fibrosis and promote liver cell regeneration drugs, under the guidance of experienced doctors, adhere to the treatment, with the development of science and research The future of overcoming chronic hepatitis B is bright with the development of science and in-depth research.